NIKKEI 225
38,764.40 +528.33 (+1.38%) HANG SENG
18,420.38 -157.92 (-0.85%) CRUDE OIL
78.70 +0.22 (+0.28%) GOLD FUTURES
2,333.00 +1.80 (+0.08%) DOW
38,852.27 +176.59 (+0.46%) Bitcoin GBP
50,338.76 -496.09 (-0.98%)
HOOKIPA Pharma Inc. (HOOK)
After hours:
| Previous close | 0.9302 |
| Open | 0.9200 |
| Bid | 0.8775 x 200 |
| Ask | 0.8935 x 100 |
| Day's range | 0.8502 - 0.9400 |
| 52-week range | 0.4100 - 2.0500 |
| Volume | |
| Avg. volume | 801,955 |
| Market cap | 92.043M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Benzinga
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers. In January, Roche terminated the collaboration and licensing agreement for HOOKIPA’s HB-700 program in KRAS mutated cancers. HOOKIPA’s HB-700 program is designed to treat KRAS-mutated lung, colorectal, pancreatic, and other cancers by targeting the five most prevalent KRAS mutat
- Simply Wall St.
Time To Worry? Analysts Just Downgraded Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Outlook
Today is shaping up negative for HOOKIPA Pharma Inc. ( NASDAQ:HOOK ) shareholders, with the analysts delivering a...
- Zacks
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
HOOKIPA Pharma (HOOK) delivered earnings and revenue surprises of 45% and 105.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
